Citigroup Lowers Caris Life Sciences (NASDAQ:CAI) Price Target to $28.00

Caris Life Sciences (NASDAQ:CAI) had its price target decreased by equities research analysts at Citigroup from $35.00 to $28.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price would indicate a potential upside of 73.37% from the stock’s current price.

CAI has been the subject of a number of other research reports. Robert W. Baird set a $22.00 target price on shares of Caris Life Sciences in a research report on Friday. JPMorgan Chase & Co. dropped their target price on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday. The Goldman Sachs Group initiated coverage on shares of Caris Life Sciences in a research report on Wednesday, April 1st. They set a “buy” rating and a $27.00 target price for the company. Jefferies Financial Group assumed coverage on Caris Life Sciences in a report on Monday, April 13th. They issued a “buy” rating and a $28.00 price target for the company. Finally, Canaccord Genuity Group lowered their price objective on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a research report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Caris Life Sciences presently has an average rating of “Moderate Buy” and an average target price of $27.56.

Caris Life Sciences Stock Performance

Shares of CAI stock traded down $3.69 during mid-day trading on Friday, reaching $16.15. The company’s stock had a trading volume of 8,860,972 shares, compared to its average volume of 2,445,794. Caris Life Sciences has a 1-year low of $15.71 and a 1-year high of $42.50. The company has a market capitalization of $4.56 billion and a P/E ratio of -89.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85. The firm’s 50-day moving average is $19.15.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The business had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. The company’s quarterly revenue was up 125.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.73) EPS. Sell-side analysts anticipate that Caris Life Sciences will post 0.12 EPS for the current year.

Institutional Investors Weigh In On Caris Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC increased its position in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Caris Life Sciences by 839.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after acquiring an additional 1,469 shares in the last quarter. Olistico Wealth LLC acquired a new stake in Caris Life Sciences in the 4th quarter valued at about $31,000. Fifth Third Bancorp acquired a new stake in Caris Life Sciences in the 1st quarter valued at about $31,000. Finally, Sterling Capital Management LLC increased its position in Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after acquiring an additional 1,083 shares in the last quarter.

Key Stories Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q1 results showed strong top‑line growth — Caris reported total revenue of $216.2M, up 79% year‑over‑year, driven by molecular profiling services, which supports the company’s growth thesis. PR Newswire — Q1 Results
• Positive Sentiment: Management’s earnings call was characterized by some observers as signaling a “profitable surge,” reinforcing that revenue growth is translating toward better profitability metrics — a constructive fundamental datapoint for investors. TipRanks — Earnings Call Highlights
• Neutral Sentiment: Full Q1 earnings call transcript and presentation are available for investors who want the details (useful for modeling and verifying management commentary). Seeking Alpha — Q1 Earnings Transcript Seeking Alpha — Presentation
• Neutral Sentiment: Company updated FY‑2026 guidance at the call, but the published entry contains garbled figures; investors are parsing management’s guide for clarity — ambiguous guidance often increases short‑term volatility.
• Negative Sentiment: JPMorgan cut its price target from $35 to $30 (maintaining an Overweight rating). The downgrade in target reduces near‑term sentiment even though the target still implies significant upside vs. the current price. Benzinga — JPMorgan PT Cut TickerReport — JPMorgan
• Negative Sentiment: BTIG trimmed its price target from $38 to $32 (still a Buy). Another analyst PT cut compounds selling pressure despite the retained positive ratings. Benzinga — BTIG PT Cut The Fly — BTIG

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.